Breast cancer-specific quality of life (EORTC QLQ-BR23) scores between CAM users and non-CAM users ^a.

<p>^a Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>^b 58 sexually active patients responded</p><p>^c 125 sexually active patients responded</p><p>*Significance level at <i>p</i> < 0.05</p><p>Breast cancer-specific quality of life (EORTC QLQ-BR23) scores between CAM users and non-CAM users <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t005fn001" target="_blank">^a</a>.</p

Factors associated with high and low global health status (QOL) (N = 308)^a^,^b.

<p>^a Other ethnic groups were excluded in the analysis</p><p>^b CAM modality used by less than 10% of CAM users was excluded from the analysis</p><p>* Significance level at <i>p</i> < 0.05</p><p>**Significance level at <i>p</i> < 0.01</p><p>***Significance level at <i>p</i> < 0.001</p><p>Factors associated with high and low global health status (QOL) (N = 308)<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t007fn001" target="_blank">^a</a>^,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t007fn002" target="_blank">^b</a>.</p

Pattern of CAM usage (N = 386).

<p>Pattern of CAM usage (N = 386).</p

Quality of life (EORTC QLQ-C30) scores among CAM users^a.

<p>^a Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>*Significance level at <i>p</i> < 0.05</p><p>Quality of life (EORTC QLQ-C30) scores among CAM users<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t004fn001" target="_blank">^a</a>.</p

Quality of life (EORTC QLQ-C30) scores between CAM users and non-CAM users ^a.

<p>^a Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>*Significance level at <i>p</i> < 0.05</p><p>Quality of life (EORTC QLQ-C30) scores between CAM users and non-CAM users <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t003fn001" target="_blank">^a</a>.</p

Breast cancer-specific quality of life (EORTC QLQ-BR23) scores among CAM users^a.

<p>^a Adjusted for total symptom burden, and demographic, disease and treatment characteristics</p><p>^b A total of 20 MBP users reported as being sexually active answered these</p><p>^c A total of 51 MBP-NP users reported as being sexually active answered these</p><p>^d A total of 39 MBP-NP-TM users reported as being sexually active answered these</p><p>*Significance level at <i>p</i> < 0.05</p><p>Breast cancer-specific quality of life (EORTC QLQ-BR23) scores among CAM users<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0139952#t006fn001" target="_blank">^a</a>.</p

The comparison of anxiety and depression scores between breast cancer patients with high or low perceived level of distress (N = 211).

<p>The comparison of anxiety and depression scores between breast cancer patients with high or low perceived level of distress (N = 211).</p

The correlation between changes in perceived distress with the changes in anxiety and depression scores among the breast cancer patients (N = 211).

<p>The correlation between changes in perceived distress with the changes in anxiety and depression scores among the breast cancer patients (N = 211).</p

Characteristics of the subjects (N = 221).

<p>Characteristics of the subjects (N = 221).</p

Patient, tumor characteristics and treatment along with the unadjusted Hazard Ratio for all cause mortality.

*<p>indicates valid proportions have been calculated (i.e., not considering unknown).</p